New $475M credit lines expiring in 2030 enable APLS to pay off debt due in 2027.
APLS’ Syfovre is not an especially good drug (#msg-173940338), but there is apparently no shortage of lenders to refinance debt of companies with FDA-approved products.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.